Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan · Delayed Price · Currency is JPY 2,070.00
-51.00 (-2.40%)
Aug 25, 2026, 3:30 PM JST
Zeria Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 91,118 | 89,159 | 87,311 | 75,725 | 68,383 | 59,532 | |
Revenue Growth | 6.76% | 2.12% | 15.30% | 10.74% | 14.87% | 7.38% |
Cost of Revenue | 24,615 | 23,976 | 23,351 | 20,224 | 18,895 | 17,384 |
Gross Profit | 66,503 | 65,183 | 63,960 | 55,501 | 49,488 | 42,148 |
Selling, General & Admin | 43,701 | 42,811 | 41,806 | 36,834 | 32,646 | 30,993 |
Research & Development | 3,709 | 3,709 | 4,106 | 3,726 | 3,456 | 4,789 |
Operating Expenses | 53,698 | 52,808 | 51,762 | 45,879 | 40,473 | 35,782 |
Operating Income | 12,805 | 12,375 | 12,198 | 9,622 | 9,015 | 6,366 |
Interest Expense | -511.18 | -501 | -452 | -457 | -337 | -315 |
Interest & Investment Income | 503.77 | 478 | 623 | 438 | 296 | 209 |
Earnings From Equity Investments | -180 | -180 | -276 | -76 | - | - |
Currency Exchange Gain (Loss) | -1,967 | -1,356 | 634 | -1,182 | -1,416 | -329 |
Other Non Operating Income (Expenses) | 161.73 | 226 | 113 | 167 | 19 | 2 |
EBT Excluding Unusual Items | 10,812 | 11,042 | 12,840 | 8,512 | 7,577 | 5,933 |
Gain (Loss) on Sale of Investments | 168 | 168 | -208 | 499 | 19 | 14 |
Gain (Loss) on Sale of Assets | -1.98 | -2 | 2 | 2 | 1 | 3 |
Asset Writedown | -6.21 | -9 | -15 | -482 | -6 | -4 |
Other Unusual Items | - | - | -2 | 977 | -321 | -226 |
Pretax Income | 10,972 | 11,199 | 12,617 | 9,508 | 7,270 | 5,720 |
Income Tax Expense | 2,705 | 2,782 | 2,650 | 1,813 | 1,065 | 1,746 |
Earnings From Continuing Operations | 8,267 | 8,417 | 9,967 | 7,695 | 6,205 | 3,974 |
Minority Interest in Earnings | -37.87 | 37 | -31 | 36 | -10 | -13 |
Net Income | 8,229 | 8,454 | 9,936 | 7,731 | 6,195 | 3,961 |
Net Income to Common | 8,229 | 8,454 | 9,936 | 7,731 | 6,195 | 3,961 |
Net Income Growth | 20.77% | -14.92% | 28.52% | 24.79% | 56.40% | 27.00% |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 45 |
Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | 45 |
Shares Change | - | - | -0.00% | -0.21% | -2.14% | -2.02% |
EPS (Basic) | 186.70 | 191.79 | 225.41 | 175.39 | 140.24 | 87.75 |
EPS (Diluted) | 186.70 | 191.79 | 225.41 | 175.39 | 140.24 | 87.75 |
EPS Growth | 20.77% | -14.92% | 28.52% | 25.06% | 59.82% | 29.62% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 7,594 | 11,493 | 9,283 | 10,757 | 7,886 |
Free Cash Flow Per Share | - | 172.28 | 260.73 | 210.59 | 243.52 | 174.71 |
Dividend Per Share | 49.000 | 49.000 | 47.000 | 44.000 | 40.000 | 35.000 |
Dividend Growth | 4.25% | 4.25% | 6.82% | 10.00% | 14.29% | 2.94% |
Gross Margin | - | 73.11% | 73.26% | 73.29% | 72.37% | 70.80% |
Operating Margin | 14.05% | 13.88% | 13.97% | 12.71% | 13.18% | 10.69% |
Profit Margin | 9.03% | 9.48% | 11.38% | 10.21% | 9.06% | 6.65% |
Free Cash Flow Margin | - | 8.52% | 13.16% | 12.26% | 15.73% | 13.25% |
EBITDA | 20,099 | 19,721 | 19,752 | 17,177 | 15,163 | 11,765 |
EBITDA Margin | - | 22.12% | 22.62% | 22.68% | 22.17% | 19.76% |
D&A For EBITDA | 7,294 | 7,346 | 7,554 | 7,555 | 6,148 | 5,399 |
EBIT | 12,805 | 12,375 | 12,198 | 9,622 | 9,015 | 6,366 |
EBIT Margin | - | 13.88% | 13.97% | 12.71% | 13.18% | 10.69% |
Effective Tax Rate | - | 24.84% | 21.00% | 19.07% | 14.65% | 30.52% |
Advertising Expenses | - | 6,301 | 5,650 | 5,290 | 4,379 | 3,546 |